- Home
- GHI vs FHTX Comparison
GHI vs FHTX Comparison
Compare GHI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- FHTX
- Stock Information
- Founded
- GHI 1998
- FHTX 2015
- Country
- GHI United States
- FHTX United States
- Employees
- GHI N/A
- FHTX N/A
- Industry
- GHI Finance: Consumer Services
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- GHI Finance
- FHTX Health Care
- Exchange
- GHI Nasdaq
- FHTX Nasdaq
- Market Cap
- GHI 269.5M
- FHTX 271.5M
- IPO Year
- GHI N/A
- FHTX 2020
- Fundamental
- Price
- GHI $11.02
- FHTX $4.99
- Analyst Decision
- GHI Strong Buy
- FHTX Strong Buy
- Analyst Count
- GHI 4
- FHTX 8
- Target Price
- GHI $16.00
- FHTX $12.63
- AVG Volume (30 Days)
- GHI 42.9K
- FHTX 121.4K
- Earning Date
- GHI 08-07-2025
- FHTX 08-07-2025
- Dividend Yield
- GHI 13.39%
- FHTX N/A
- EPS Growth
- GHI N/A
- FHTX N/A
- EPS
- GHI 0.45
- FHTX N/A
- Revenue
- GHI $34,065,322.00
- FHTX $23,504,000.00
- Revenue This Year
- GHI $228.92
- FHTX $33.60
- Revenue Next Year
- GHI $4.27
- FHTX $5.87
- P/E Ratio
- GHI $24.69
- FHTX N/A
- Revenue Growth
- GHI N/A
- FHTX N/A
- 52 Week Low
- GHI $10.12
- FHTX $2.95
- 52 Week High
- GHI $15.27
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- GHI 41.10
- FHTX 40.37
- Support Level
- GHI $10.81
- FHTX $6.00
- Resistance Level
- GHI $11.45
- FHTX $6.79
- Average True Range (ATR)
- GHI 0.25
- FHTX 0.42
- MACD
- GHI -0.00
- FHTX -0.16
- Stochastic Oscillator
- GHI 28.77
- FHTX 3.37
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.